Related references
Note: Only part of the references are listed.Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
Corneel Coens et al.
LANCET ONCOLOGY (2020)
Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: A practical guide
Suzie Cro et al.
STATISTICS IN MEDICINE (2020)
The proportion of missing data should not be used to guide decisions on multiple imputation
Paul Madley-Dowd et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts
Janus Christian Jakobsen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Missing Data
James H. Ware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Prevention and Treatment of Missing Data in Clinical Trials
Roderick J. Little et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Impact of Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on Prediction of Recurrence in Primary Brain Tumor Patients
Terri S. Armstrong et al.
CANCER (2011)
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
T. S. Armstrong et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Share Paper
